tiprankstipranks
Advertisement
Advertisement

BNTX Stock Latest News

BioNTech Earnings Call: Cash-Rich Pivot Beyond COVID
Company AnnouncementsBioNTech Earnings Call: Cash-Rich Pivot Beyond COVID
2d ago
BNTX
BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
PremiumCompany Announcements
BioNTech Calls Virtual 2026 AGM, Seeks Larger Supervisory Board to Back Oncology Push
4d ago
6K
BNTX
BioNTech price target lowered to $130 from $140 at H.C. Wainwright
PremiumThe Fly
BioNTech price target lowered to $130 from $140 at H.C. Wainwright
7d ago
BNTX
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
PremiumCompany Announcements
BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
11d ago
BNTX
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
PremiumCompany Announcements
BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
13d ago
6K
BNTX
District court rules federal limits to vaccines not based on science, NYT says
PremiumThe FlyDistrict court rules federal limits to vaccines not based on science, NYT says
21d ago
AZN
BMY
BioNTech price target lowered to $94 from $116 at TD Cowen
Premium
The Fly
BioNTech price target lowered to $94 from $116 at TD Cowen
27d ago
BNTX
BioNTech price target lowered to $125 from $134 at Morgan Stanley
Premium
The Fly
BioNTech price target lowered to $125 from $134 at Morgan Stanley
27d ago
BNTX
BioNTech price target lowered to $128 from $143 at BMO Capital
PremiumThe Fly
BioNTech price target lowered to $128 from $143 at BMO Capital
27d ago
BNTX
BioNTech price target lowered to $130 from $145 at Citi
PremiumThe Fly
BioNTech price target lowered to $130 from $145 at Citi
27d ago
BNTX
Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
PremiumRatings
Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
27d ago
BNTX
BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
PremiumRatings
BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
28d ago
BNTX
Jefferies cuts BioNTech price target, says stock is cheap
PremiumThe FlyJefferies cuts BioNTech price target, says stock is cheap
28d ago
BNTX
Clear Street lowers BioNTech price target, says buy on weakness
Premium
The Fly
Clear Street lowers BioNTech price target, says buy on weakness
28d ago
BNTX
BioNTech falls -19.9%
Premium
The Fly
BioNTech falls -19.9%
28d ago
BNTX
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
PremiumThe Fly
Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company
28d ago
ABM
CNC
BioNTech falls -20.3%
PremiumThe Fly
BioNTech falls -20.3%
28d ago
BNTX
Morning Movers: BioNTech sinks following departure of founders, Q4 results
PremiumThe Fly
Morning Movers: BioNTech sinks following departure of founders, Q4 results
28d ago
BG
HPE
Options Volatility and Implied Earnings Moves Today, March 10, 2026
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, March 10, 2026
28d ago
FNV
KSS
BioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
PremiumCompany AnnouncementsBioNTech Posts 2025 Loss but Leans on Strong Cash and Late-Stage Oncology Pipeline
28d ago
6K
BNTX
BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
Premium
Company Announcements
BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline
28d ago
6K
BNTX
BioNTech reports Q4 adjusted EPS EUR (0.33) vs. EUR 1.79 last year
Premium
The Fly
BioNTech reports Q4 adjusted EPS EUR (0.33) vs. EUR 1.79 last year
28d ago
BNTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >